Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Mallinckrodt
AstraZeneca
Dow

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,758,998

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,758,998
Title:Construction of bifunctional short hairpin RNA
Abstract: A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more target site sequences; providing a backbone sequence comprising a first and a second stem-loop structure, inserting a first passenger strand and a second passenger strand and providing for synthesis of the bi-shRNA expression cassette.
Inventor(s): Rao; Donald (Dallas, TX)
Assignee: Gradalis, Inc. (Carrollton, TX)
Application Number:13/364,053
Patent Claims:1. A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more first target site sequences of a targeted species, wherein the one or more first target site sequences have low homology with other mRNAs of the targeted species, wherein low homology is selected from the group consisting of less than 75%, less than 80%, less than 90%, less than 95%, and less than 98% homology; selecting one or more second target site sequences of a targeted species, wherein the one or more first target site sequences have low homology with other mRNAs of the targeted species, wherein low homology is selected from the group consisting of less than 75%, less than 80%, less than 90%, less than 95%, and less than 98% homology; providing a backbone sequence comprising a first and a second stem-loop structure, wherein the first stem-loop structure comprises two first insertion sites linked by a first loop sequence within the first stem and wherein the second stem-loop structure comprises two second insertion sites linked by a second loop sequence within the second stem; wherein the first and the second stem-loop structures are linked by a sequence longer than 5 nucleotides; inserting a first passenger strand and a first guide strand into the two first insertion sites to form the first stem, wherein the first passenger strand is homologous to the one or more first target site sequences and wherein the first guide strand is complementary to the first passenger strand, or wherein the first passenger strand is identical to the reverse orientation of the first guide strand; and inserting a second passenger strand and a second guide strand into the two second insertion sites to form the second stem-loop structure, wherein either the second passenger strand or the second guide strand is homologous with the one or more first target site sequences, or wherein either the second passenger strand or the second guide strand is homologous with the one or more second target sites sequences, wherein the second passenger strand and the second guide strand are partially complementary, wherein partially complementary is defined has having 1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, or 1-10 nucleotide mismatches when paired.

2. The method of claim 1, wherein the first stem-loop structure and the second stem-loop structure each comprise a loop of 6-15 nucleotides in size.

3. The method of claim 1, wherein the first stem-loop structure and the second stem-loop structure are each 40 to 100 nucleotides long.

4. The method of claim 1, wherein the first stem-loop structure and the second stem-loop structure are each 50 to 75 nucleotides long.

5. The method of claim 1, wherein the first stem-loop structure and the second stem-loop structure each comprise a stem of 19-45 nucleotides in size.

6. The method of claim 1, wherein the first stem-loop structure and the second stem-loop structure each comprise a stem of 20-30 nucleotides in size.

7. The method of claim 1, wherein at least one passenger strand and one guide strand are 16-19 nucleotides long.

8. The method of claim 1, wherein at least one passenger strand and one guide strand are 19-22 nucleotides long.

9. The method of claim 1, wherein the first loop and the second loop are identical.

10. The method of claim 1, wherein the first loop encodes the sequence AGUGAAGCCACAGAUGU (SEQ ID NO.:1).

11. The method of claim 1, wherein the backbone sequence comprises the following sequence upstream of the second passenger strand and within the second stem: GCUGUUGACAGUGAGCGCC (SEQ ID NO.:5); and wherein the backbone sequence comprises the following sequence downstream of the second guide strand and within the second stem: GUUGCCUACUGCCUCGGAAGC (SEQ ID NO.:6).

12. The method of claim 1, wherein the one or more nucleotide mismatches are located at nucleotide position 9, 10, and 11.

13. The method of claim 1, further comprising determining a .DELTA.G free energy of the second stem loop structure and introducing additional mismatches at the 3' half of the second passenger strand if .DELTA.G free energy is beyond about -10Kcalmole.sup.-1.

14. The method of claim 1, wherein the bi-shRNA expression cassette further comprises a lead transcript upstream of the stem-loop structures.

15. The method of claim 1, further comprising designing at least three bi-shRNA expression cassettes for the same gene; and comparing knockdown efficiency of the at least three bi-shRNA expression cassettes by in vitro assessment.

16. The method of claim 1, further comprising operably linking the bi-shRNA expression cassette to a promoter, wherein the first stem-loop structure is upstream in relation to the second stem loop structure.

17. The method of claim 1, further comprising integrating the bi-shRNA expression cassette into genomic DNA, wherein the genomic DNA is human DNA.

18. The method of claim 1, further comprising inserting the bi-shRNA expression cassette into an expression vector.

19. The method of claim 14, wherein the expression vector comprises a 5'UTR and an intron.

20. The method of claim 14, wherein the expression vector comprises a RNA polymerase II promoter operably linked to the expression of the bi-shRNA expression cassette.

21. The method of claim 1, wherein the backbone sequence comprises a miR30a backbone sequence.

22. The method of claim 1, wherein selecting one or more target site sequences comprises searching by BLAST to find target sites with lowest homology hits to other mRNA of the targeted species.

23. The method of claim 1, wherein providing for synthesis is selected from the group comprising assembling multiple overlapping DNA oligonucleotides, synthesizing a polynucleotide, and combinations thereof.

24. The method of claim 1, wherein providing for synthesis comprises designing DNA oligonucleotides from both strands having an overlap, wherein the overlap is at least four nucleotides.

25. The method of claim 1, further comprising preparing a DNA-DOTAP:Chol Lipoplex.

26. The method of claim 1, wherein the one or more first target site sequences and the one or more second target site sequence are not identical and located within the same gene of the targeted species.

27. The method of claim 1, further comprising transcribing the bi-shRNA expression cassette.

28. The method of claim 27, wherein the bi-shRNA expression cassette is integrated into genomic DNA.

29. The method of claim 1, further comprising integrating the bi-shRNA expression cassette into a crop genomic DNA, wherein crop is a non-animal species or variety that is grown to be harvested as food, livestock fodder, fuel or for any other economic purpose.

30. The method of claim 1, further comprising the step of providing for synthesis of the bi-shRNA expression cassette.

31. The method of claim 1, wherein the targeted species comprises a human nucleic acid sequence.

Details for Patent 8,758,998

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   See Pricing Gradalis, Inc. (Carrollton, TX) 2026-11-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   See Pricing Gradalis, Inc. (Carrollton, TX) 2026-11-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   See Pricing Gradalis, Inc. (Carrollton, TX) 2026-11-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,758,998

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Harvard Business School
Dow
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.